NEW YORK (GenomeWeb) – Alere on Thursday reported that its second quarter revenues fell 9 percent year over year, driven primarily by sinking sales in its cardiometabolic disease and infectious disease test segments.

For the three months ended June 30, the firm reported revenues of $557.7 million compared to restated revenues of $610.3 million in Q2 2016. The firm said that its financial results for Q2 reflect a $6 million negative impact of foreign currency exchange.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.